Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?

Bibliography

• DURRINGTON P: Dyslipidaemia. Lancet (2003) 362:717-731.
   PubMed Web of Science ®Google Scholar
• PACKARD CJ: Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr. Opin. Lipidol. (2006) 17:412-417.
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
   PubMed Web of Science ®Google Scholar
• THE TASK FORCE ON DIABETESAND CARDIOVASCULAR DISEASES OF THE EUROPEAN SOCIETY OF CARDIOLOGY(ESC) AND THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD): Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur. Heart J. (2007) 28:88-136.
   PubMedGoogle Scholar
• GRUNDY SM, CLEEMAN JI, MERZ CNB et al. FOR THE COORDINATING COMMITTEE OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM: Implications or recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110:227-239.
   PubMed Web of Science ®Google Scholar
• DE BACKER G, AMBROSIONI E, BORCH-JONSEN K et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. (2003) 24:1601-1610.
   PubMed Web of Science ®Google Scholar
• ROBINS SJ, COLLINS D, WITTES JT et al. FOR THE VA-HIT STUDY GROUP: Relation of gemfibrozil treatment and lipid levels with major coronary events – VA-HIT: a randomized controlled trial. JAMA (2001) 285(12):1585-1591.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. (2002) 162:2597-2604.
   PubMed Web of Science ®Google Scholar
• TENENBAUM A, MOTRO M, FISMAN EZ et al.: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. (2005) 165:1154-1160.
   PubMed Web of Science ®Google Scholar
• THE BIP STUDY GROUP: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation (2000) 102:21-27.
   PubMed Web of Science ®Google Scholar
• THE FIELD STUDY INVESTIGATORS: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet (2005) 366(9500):1849-1861.
   PubMed Web of Science ®Google Scholar
• FARNIER M: Combined therapy with a HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am. J. Cardiovasc. Drugs (2003); 3(3):169-178.
   PubMedGoogle Scholar
• CORSINI A, BELLOSTA S, DAVIDSON MH: Pharmacokinetic interactions between statins and fibrates. Am. J. Cardiol. (2005) 96(Suppl.): 44K-49K.
   Web of Science ®Google Scholar
• ALSHEIKH-ALI AA, KUVIN JT, KARAS RH: Risk of adverse events with fibrates. Am. J. Cardiol. (2004) 94:935-938.
   PubMed Web of Science ®Google Scholar
• JONES PH, DAVIDSON MH : Reporting rate of rhadomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. (2005) 95:120-122.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J: The role of the exogenous pathway in hypercholesterolemia. Eur. Heart J. (2001) 3(Suppl. E): E2-E5.
   Google Scholar
• CATAPANO AL: Ezetimibe: a selective inhibitor of cholesterol absorption. Eur. Heart J. (2001) 3(Suppl.): E6-E10.
   Web of Science ®Google Scholar
• SUDHOP T, LUTJOHANN D, VON BERGMANN K: Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol. Ther. (2005) 105:333-341.
   PubMed Web of Science ®Google Scholar
• ALTMANN SW, DAVIS Jr HR, ZHU L et al.: Niemann-Pick C1-Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 303:1201-1204.
   PubMed Web of Science ®Google Scholar
• GARCIA-CALVO M, LISNOCK JM, BULL HG et al.: The target of ezetimibe is Niemann-Pick C1-Like1 (NPC1L1). Proc. Natl. Acad. Sci. USA (2005) 102(23):8132-8137.
   PubMed Web of Science ®Google Scholar
• DAVIES JP, IOANNOU YA: The role of the Niemann-Pick C1-Like1 protein in the subcellular transport of multiple lipids and their homeostasis. Curr. Opin. Lipidol. (2006) 7:221-226.
   Google Scholar
• SMART EJ, De ROSE RA, FARBER SA: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci. USA (2004) 101(10):3450-3455.
   PubMed Web of Science ®Google Scholar
• JEU LA, CHENG JWM: Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin. Ther. (2003) 25(9):2352-2387.
   PubMed Web of Science ®Google Scholar
• GHOSAL A, HAPANGAMA N, YUAN Y et al.: Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab. Dispos. (2004) 32(3):314-320.
   PubMed Web of Science ®Google Scholar
• VAN HEEK M, FARLEY C, COMPTON DS et al.: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. (2000) 129:1748-1754.
   PubMed Web of Science ®Google Scholar
• DARKES MJM, POOLE RM, GOA KL: Ezetimibe. Am. J. Cardiovasc. Drugs (2003) 3(1):67-76.
   PubMedGoogle Scholar
• SUDHOP T, LUTJOHANN D, KODAL A et al.: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation (2002) 106:1943-1948.
   PubMed Web of Science ®Google Scholar
• FRUCHART JC, BREWER HB, LEITERSDORF E: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am. J. Cardiol. (1998) 81:912-917.
   PubMed Web of Science ®Google Scholar
• FRUCHART JC, STAELS B, DURIEZ P: The role of fibric acids in atherosclerosis. Curr. Atheroscl. Rep. (2001) 3:83-92.
   PubMedGoogle Scholar
• STAELS B, DALLONGEVILLE J, AUWERX J, SCHOONJANS K, LEITERSDORF E, FRUCHART JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 98:2088-2093.
   PubMed Web of Science ®Google Scholar
• FAZIO S, LINTON MF: The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscl. Rep. (2004) 6:148-157.
   PubMedGoogle Scholar
• ADKINS JC, FAULDS D: Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs (1997) 54(4):615-633.
   PubMed Web of Science ®Google Scholar
• KEATING GM, ORMROD D: Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs (2002) 62(13):1909-1944.
   PubMed Web of Science ®Google Scholar
• KEATING GM, CROOM KF: Fenofibrate. A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs (2007) 67(1):121-153.
   PubMed Web of Science ®Google Scholar
• CHAPMAN MJ: Fibrates: therapeutic review. Br. J. Diabetes Vasc. Dis. (2006) 6(1):11-18.
   Google Scholar
• GUERIN M, BRUCKERT E, DOLPHIN PJ et al.: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. (1996) 16(6):763-772.
   PubMed Web of Science ®Google Scholar
• FRUCHART JC, DURIEZ P: Mode of action of fibrates in the regulation of triglycerides and HDL-cholesterol metabolism. Drugs Today (2006) 42(1):39-64.
   PubMed Web of Science ®Google Scholar
• KOSOGLOU T, STATKEVICH P, FRUCHART JC et al.: Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr. Med. Res. Opin. (2004) 20(8):1197-1207.
   PubMed Web of Science ®Google Scholar
• STEIN E: Results of Phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur. Heart J. (2001) 3(Suppl. E): E11-E16.
   Web of Science ®Google Scholar
• DUJOVNE CA, ETTINGER MP, McNEER JF et al. FOR THE EZETIMIBE STUDY GROUP: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. (2002) 90:1092-1097.
   PubMed Web of Science ®Google Scholar
• KNOPP RH, GITTER H, TRUITT T et al. FOR THE EZETIMIBE STUDY GROUP: Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. (2003) 24:729-741
   PubMed Web of Science ®Google Scholar
• BAYS HE, MOORE PB, DREHOBL MA et al. FOR THE EZETIMIBE STUDY GROUP: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. (2001) 23(8):1209-1230.
   PubMed Web of Science ®Google Scholar
• KOH KK, HAN SH, QUON MJ et al.: Benefical effects of fenofibrate to improve endothelial dysfunction and raise adinopectin levels in patients with primary hypertriglyceridemia. Diabetes Care (2005) 28(6):1419-1424.
   PubMed Web of Science ®Google Scholar
• CAPELL WH, DeSOUZA CA, POIRIER P et al.: Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. (2003) 23:307-313.
   PubMed Web of Science ®Google Scholar
• LIAMIS G, BAIRAKTARI ET, ELISAF MS: Effect of fenofibrate on serum uric acid levels. Am. J. Kidney Dis. (1999) 34: 594.
   PubMed Web of Science ®Google Scholar
• TSIMICHODIMOS V, BAIRAKTARI E, ELISAF M: Fibrate-induced increase in serum urea and creatinine levels. Nephrol. Dial. Transplant (2002) 17(4):682.
   PubMed Web of Science ®Google Scholar
• DIERKES J, WESTPHAL S, LULEY C: Fenofibrate-induced hyperhomocysteinaemia. Clinical implications and management. Drug Saf. (2003) 26(2):81-91.
   PubMed Web of Science ®Google Scholar
• DIABETES ATHEROSCLEROSISINTERVENTION STUDY INVESTIGATORS: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study. Lancet (2001) 357(9260):905-910.
   PubMed Web of Science ®Google Scholar
• VAKKILAINEN J, STEINER G, ANSQUER JC et al.: Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation (2003) 107:1733-1737.
   PubMed Web of Science ®Google Scholar
• GENEST J, FROHLICH J, STEINER G: Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am. J. Cardiol. (2004) 93(7):848-853.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDYCOLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361:2005-2016.
   PubMed Web of Science ®Google Scholar
• COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al. ON BEHALF OF THE CARDS INVESTIGATORS: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364:685-696.
   PubMed Web of Science ®Google Scholar
• SYVANNE M, WHITTALL RA, TURPEINEN U et al.: Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis (2004) 172:267-272.
   PubMed Web of Science ®Google Scholar
• FRICK MH, ELO O, HAAPA K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. (1987) 317:1237-1245.
   PubMed Web of Science ®Google Scholar
• MIKAEL LG, GENEST J Jr, ROZEN R: Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. (2006) 98:564-571.
   PubMed Web of Science ®Google Scholar
• ANSQUER JC, FOUCHER C, RATTIER S, TASKINEN MR, STEINER G, DAIS INVESTIGATORS: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. (2005) 45(3):485-493.
   PubMed Web of Science ®Google Scholar
• UNDAS A, BROZEK J, SZCZEKLIK A: Homocysteine and thrombosis: from basic science to clinical evidence. Thromb. Haemost. (2005) 94:907-915.
   PubMed Web of Science ®Google Scholar
• FARNIER M, FREEMAN MW, MacDONELL G et al.: Efficacy and safety of the co-administration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. Eur. Heart J. (2005) 26:897-905.
   PubMed Web of Science ®Google Scholar
• McKENNEY JM, FARNIER M, LO KW et al.: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. (2006) 47(8):1584-1587.
   PubMed Web of Science ®Google Scholar
• CHOLESTEROL TREATMENTTRIALIST’S (CTT) COLLABORATORS: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet (2005) 366:1267-1278.
   PubMed Web of Science ®Google Scholar